http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#Head http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#assertion http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#provenance http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#pubinfo http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#assertion http://purl.obolibrary.org/obo/DOID_1040 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_1040 http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB06769 http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#association http://www.w3.org/2000/01/rdf-schema#label bendamustine hydrochloride injection is an alkylating drug indicated for treatment of patients with chronic lymphocytic leukemia cll efficacy relative to first line therapies other than chlorambucil has not been established 1 1 indolent b cell non hodgkin lymphoma nhl that has progressed during or within six months of treatment with rituximab or a rituximab containing regimen 1 2 bendamustine hydrochloride injection is indicated for the treatment of patients with chronic lymphocytic leukemia efficacy relative to first line therapies other than chlorambucil has not been established bendamustine hydrochloride injection is indicated for the treatment of patients with indolent b cell non hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab containing regimen http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB06769 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#provenance http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#pubinfo http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#sig http://purl.org/nanopub/x/hasSignature GqyRk24dx5beTXKfGlW3ci8maICZ8+4mY5osqfCLIb+5MEmMrwpGvFLHSbhiNmgENgmI8mMWHO1YTwHmQu68KG4hX07WINWpInFxqiy8eYhT1yhGn0Sfdzl+ZidIubsvzNjVyTuA6Fh4aspkVlIqW88Tcwfqk6vfusERm6x9Kx0= http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs http://purl.org/dc/terms/created 2021-06-30T09:01:14.488+02:00 http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs